[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350075-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-350075-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","breast-and-ovarian-cancers-toward-a-multi-cancer-early-detection-test","Breast and ovarian cancers: toward a multi-cancer early detection test","","Breast cancer and ovarian cancer share overlapping genetic, hormonal, and microenvironmental features, motivating the search for common immune-related biomarkers that enable scalable, non-invasive early detection. A multiplex immunoassay profiled 81 immune proteins in sera from 57 breast cancer patients, 57 ovarian cancer patients, and 49 healthy controls. Multivariate and ROC analyses assessed single markers and combined panels, while interaction networks highlighted dysregulated modules. Eighteen proteins were altered in both cancers versus controls, with network centers in TNF/TNFR, co-stimulation and chemokine pathways, supporting a feasible multi-cancer diagnostic test.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/breast-and-ovarian-cancers-toward-a-multi-cancer-early-detection-test/350075/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/breast-and-ovarian-cancers-toward-a-multi-cancer-early-detection-test/350075.png","ImageObject",300,407,{"name":42,"@type":43},"WPS_1786070896","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-08","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main goal of the study on breast and ovarian cancers?","Question",{"text":63,"@type":64},"To identify shared immune-related biomarkers that could support a common multi-cancer early detection test for both breast and ovarian cancers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were biomarkers measured in the study?",{"text":68,"@type":64},"The study used a multiplex immunoassay profiling 81 immune-related proteins in serum samples from breast cancer patients, ovarian cancer patients, and healthy controls.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the analyses show about diagnostic performance and shared biology?",{"text":72,"@type":64},"Combined protein panels achieved high diagnostic accuracy, and network analysis revealed interconnected modules—centered on TNF/TNFR, co-stimulatory molecules, and chemokines—consistent with shared immune and oncogenic pathways.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350075,1790369590,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},549768072016,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","TYPE Original Research PUBLISHED 19 March 2026  \nDOI 10.3389/fimmu.2026.1741582  \nOPEN ACCESS  \nEDITED BY  \nAnand Rotte,  \nArcellx Inc, United States  \nREVIEWED BY  \nHaoming Wu,  \nShantou University, China Milena Kiljan´czyk,  \nPomeranian Medical University, Poland  \n*CORRESPONDENCE  \nAzza Habel  \n [azza.habel1@gmail.com](azza.habel1@gmail.com)  \nRECEIVED 07 November 2025  \nREVISED 16 February 2026  \nACCEPTED 24 February 2026  \nPUBLISHED 19 March 2026  \nCITATION  \nHabel A, Bessaad M, stayoussef M, Xu W, Bouaziz H, Ayadi M, Larbi A and Yaacoubi-Loueslati B (2026) Breast and ovarian cancers: toward a multi-cancer early detection test.  \nFront. Immunol. 17:1741582 .  \ndoi: 10.3389/fimmu.2026.1741582  \nCOPYRIGHT  \n© 2026 Habel, Bessaad, stayoussef, Xu, Bouaziz, Ayadi, Larbi and YaacoubiLoueslati. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nBreast and ovarian cancers: toward a multi-cancer early detection test  \nAzza Habel 1*, Maryem Bessaad 1, Mouna stayoussef 1, Weili Xu 2, Hanen Bouaziz 3, Mouna Ayadi 3, Anis Larbi 2,4 and Basma Yaacoubi-Loueslati 1  \n1 Laboratory of Mycology, Pathologies, and Biomarkers (LR16ES05), Faculty of Sciences of Tunis, University of Tunis El Manar, Tunis, Tunisia, 2Singapore Immunology Network (SIgN), Agency for Science Technology and Research (A*STAR), Singapore, Singapore, 3Salah Azaiez Oncology Institute, Tunis, Tunisia, 4 Beckman Coulter Life Sciences, Villepinte, France  \nIntroduction: Breast cancer (BC) and ovarian cancer (OC) are leading causes of cancer-related mortality among women worldwide. Despite their distinct clinical presentation these malignancies share genetic, hormonal, and microenvironmental characteristics, suggesting overlapping mechanisms of tumorigenesis and immune escape. Identifying common immune-related biomarkers could improve large scale early detection and guide the development of shared therapeutic strategies.  \nMethods: We conducted a multiplex immunoassay proﬁling of 81 immunerelated proteins including cytokines, chemokines, growth factors, and immune checkpoints in serum samples from 57 BC patients, 57 OC patients, and 49 healthy controls (HC) .  \nResults: Multivariate and univariate analyses were utilized to identify proteins exhibiting signiﬁcant dysregulation. Receiver Operating Characteristic (ROC) curve analyses were conducted to evaluate the diagnostic performance of individual and combined protein panels. Protein-protein interaction networks were constructed using STRING and Cytoscape to elucidate shared functional modules. Multivariate analysis revealed a partial yet signiﬁcant distinction between cancer patients and HC, with BC and OC exhibiting notable immunological similarities. Eighteen proteins were dysregulated in BC and OC as compared to HC, indicating shared oncogenic and immunological pathways. Furthermore, individual biomarkers exhibited moderate diagnostic performance, while combined panels achieved high accuracy. Network analysis revealed highly interconnected modules centered on the TNF/TNFR superfamily, costimulatory molecules, and chemokines, suggesting promising targets for combinatorial immunotherapy.  \nDisscussion: our ﬁndings demonstrate a signiﬁcant overlap in immune-related protein expression between BC and OC, supporting the feasibility of a common diagnostic biomarker panel for these female cancers. The identiﬁed proteins and their interaction networks offer valuable insights into the shared mechanisms of tumor progression and immune evasion, presenting promising avenues for early diagnosis and targeted therapy.  \nKEYWORDS  \nbreast canc","cbCaivj8Dlr6uUbO","https://ap.wps.com/l/cbCaivj8Dlr6uUbO","pdf",3474102,11,"English","# Introduction\n## Shared features and rationale for a multi-cancer panel\n## Tumor microenvironment and immune-related pathways\n# Methods\n# Results\n## Diagnostic performance of protein panels\n## Protein interaction networks and functional modules\n# Discussion","[{\"question\":\"What is the main goal of the study on breast and ovarian cancers?\",\"answer\":\"To identify shared immune-related biomarkers that could support a common multi-cancer early detection test for both breast and ovarian cancers.\"},{\"question\":\"How were biomarkers measured in the study?\",\"answer\":\"The study used a multiplex immunoassay profiling 81 immune-related proteins in serum samples from breast cancer patients, ovarian cancer patients, and healthy controls.\"},{\"question\":\"What did the analyses show about diagnostic performance and shared biology?\",\"answer\":\"Combined protein panels achieved high diagnostic accuracy, and network analysis revealed interconnected modules—centered on TNF/TNFR, co-stimulatory molecules, and chemokines—consistent with shared immune and oncogenic pathways.\"}]","Breast and ovarian cancers: toward a multi-cancer early detection test | PDF",1790087035,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7a18b9a6c2983ea837b9527bdb61a13f.webp",983,1389,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/21d7ff6ed6c4275ff1bc129d6db9a1af.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d5f65d5a7d7ae45e9a200fa2dc053652.webp",981,1386,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/76039c4711984875690571bf719340a2.webp",980,1385]